Hollencrest Capital Management Clovis Oncology, Inc. Transaction History

Hollencrest Capital Management

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 07, 2022	BUY	$2.7 - $4.76 $216,000 - $380,800	80,000 Added 200.0%	120,000 $325,000
Q2 2021 Jul 21, 2021	BUY	$5.02 - $7.05 $125,499 - $176,250	25,000 Added 166.67%	40,000 $232,000
Q1 2021 Apr 29, 2021	BUY	$4.81 - $10.34 $72,150 - $155,100	15,000 New	15,000 $105,000

166

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

Get notified when there are updates to the investment portfolio of Hollencrest Capital Management, based on Form 13F filings with the SEC.

Stay updated on Hollencrest Capital Management with notifications on news.